Q3 2026 Xenon Pharmaceuticals Inc. Earnings Conference Call - XENON PHARMACEUTICALS INC

Financial Performance:

• Entered Q3 2026 with $1.2 billion in cash, cash equivalents, and marketable securities.
• Current cash runway is sufficient to fund operations through 2029.
• Full financial results and Form 10-Q details are available in the accompanying press release; specific revenue and margin figures for Q3 2026 were not disclosed in the transcript as the company is pre-commercial for its primary asset.
• Significant capital allocated to building commercial infrastructure, pay engagement teams, and advancing late-stage clinical programs.

Guidance and Future Outlook:

• Aiming for FDA approval and U.S. launch of AZETUCALNEER (AZK) for focal seizures pending NDA acceptance.
• Top-line data for the Phase 3 Exnova-2 study in Major Depressive Disorder (MDD) accelerated to December 2026.
• Initiating the Phase 3b/4 "X-FIRST" study (AZK as first add-on) in Q1 2027; planning Phase 2 pain proof-of-concept studies in H1 2027.
• Targeting full commercial integration and launch readiness by the time of potential AZK approval.
• Management expressed strong confidence in the pipeline, citing the "full steam ahead" status for AZK launch preparations.

Business Segments and Product Lines:

• Epilepsy (AZK): NDA submitted for focal seizures; pivotal data shows a 42.7% placebo-adjusted MPC (highest in history for the indication) with a robust safety profile (1,500+ patient years). Enrolling Phase 3 X-TOL3 (global) and EXACT (primary generalized tonic-clonic seizures).
• Neuropsychiatry (AZK): Completed enrollment of 360 patients in Exnova-2 (MDD); evaluating benefit-risk profile following a voluntary pause for review of neuropsychiatric AEs. Investigating KV7 modulation for anhedonia.
• Pain (XEN-1701 & XEN-1120): Positive Phase 1 data for NAV1.7 (XEN-1701) and KV7 (XEN-1120) candidates. Achieved >75% (up to >90%) receptor occupancy in humans; demonstrated efficacy in non-human primate pain models without significant autonomic side effects. Advancing to Phase 2 in acute pain.
• Early Pipeline: Preclinical NAV1.1 program for Dravet syndrome; Phase 1b MBI 921355 (partnered with Neurocrine) expected to report data in 2027.

Market and Competitive Landscape:

• AZK differentiation centers on novel mechanism (SV2A), ease of use (no titration, once-daily), and four therapeutic dose levels.
• High physician enthusiasm from both epileptologists (refractory patients) and general neurologists (earlier treatment settings).
• Unmet need in pain highlighted by opioid abuse risks and limited efficacy of current non-opioid options; ion channel modulators (NAV1.7) viewed as transformative.
• Competition in epilepsy acknowledged, with the last branded ASM approval being over a decade ago (SanovaMate), creating a potential first-to-market advantage for AZK.

Risks and Challenges:

• Psychiatry Safety: Voluntary pause in MDD enrollment to review mild/moderate neuropsychiatric adverse events; regulatory pathway post-Exnova-2 data remains to be finalized with the FDA.
• Commercial Adoption: Broad payer coverage may take time post-approval; requires early engagement with specialty pharmacies and payers to ensure patient access.
• Clinical Execution: Need to manage protocol adjustments and data analysis timelines for the unblinded Exnova-2 results.
• Pain Target Validation: NAV1.7 has historically been difficult to target; success relies on achieving specific receptor occupancy without the autonomic side effects plaguing prior candidates.

Management Commentary and Tone:

• Tone is highly optimistic and confident, emphasizing "full steam ahead" on the AZK launch and excitement over the pain asset progress.
• Management highlighted the "compelling profile" of AZK and the "unprecedented" nature of the pain data (NAV1.7 inhibition mimicking human genetics).
• Acknowledged the strategic shift toward a fully integrated commercial company with a focus on "frictionless" patient and HCP experience.
• Reiterated commitment to moving AZK earlier in the treatment paradigm via the X-FIRST study to capture the general neurology market.

Analyst Questions and Answers:

• Psychiatry Timeline: Expressed intent to move quickly post-Exnova-2 data release (December) but noted specific timelines for FDA interactions and protocol changes are not being guided.
• Neuropsychiatry Priority: Psychiatry remains a key pillar; the program will proceed if Exnova-2 data supports a compelling benefit-risk profile, backed by a strong balance sheet.
• X-FIRST Study Design: Open-label study targeting general neurologists with less refractory patients to mimic real-world early-line use; data will assess clinical meaningfulness in this specific population.
• NAV1.7 Safety: Addressed a single syncope case as likely unrelated to drug (due to baseline orthostatic hypotension and timing); management remains confident in the lack of autonomic side effects compared to historical compounds.
• Olfactory Side Effects: Confirmed that smell tests were conducted in Phase 1; no systematic collection or evidence of anosmia observed, consistent with lack of clinical relevance in healthy volunteers.
• Dose Selection for Early Line: Will likely start at lower doses (10-15mg) to mimic clinical practice and safety profile, with escalation options available based on the four-dose NDA submission.
• Data Acceleration: Exnova-2 accelerated to December due to efficient data cleaning and project management, not changes to the underlying protocol.

Other Key Points:

• The company is actively engaging patient advocacy organizations and building a robust medical science liaison (MSL) team.
• AZK is expected to be the first new branded ASM in nearly a decade, potentially reshaping the therapeutic landscape.
• Focus on "ease of use" attributes (no titration, no DDI adjustments) as key drivers for adoption among general neurologists.
• Continued collaboration with partners (e.g., Neurocrine for MBI 921355).
• Management emphasized that while epilepsy is the immediate commercial focus, the pain and psychiatry pipelines offer significant long-term growth potential.